Today's special guest is Susan Garfield, DrPH, Principal | Commercial Lead | Health Sciences and Wellness Sector with Ernst & Young LLP. Susan is an author on the study titled: Reimagined the Life Sciences Beyond COVID-19
Summary:
From payer-mix changes, to pricing and profitability concerns, COVID-19 has made the biopharma industry fraught with market and other pressures. However, these circumstances have also presented new opportunities, including accelerated adoption of digital tools and approaches. This was all made clear when we, in association with EY, surveyed 550+ biopharma executives - from R&D to commercial – to gain practical insights on the current state and long-term outlook for the industry.
This new free report ‘Beyond COVID-19: Life sciences reimagined’ highlights key findings from our analysis and is intended to help establish a framework for more patient-focused, sustainable care delivery post-crisis. Download this 30+ page report and:
Download this 30+ page report for free here.
Insights from industry leaders, include: